ProfileGDS5678 / 1456768_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 94% 94% 94% 94% 94% 89% 85% 89% 88% 93% 95% 93% 94% 93% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.9791294
GSM967853U87-EV human glioblastoma xenograft - Control 28.2448694
GSM967854U87-EV human glioblastoma xenograft - Control 38.2625994
GSM967855U87-EV human glioblastoma xenograft - Control 48.2725794
GSM967856U87-EV human glioblastoma xenograft - Control 58.1981694
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.7160389
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.2748385
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.960589
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.8649988
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.8571393
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 28.267695
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.9363993
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 48.2508794
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.8892493